COVID-19 Anticoagulation in cancer

21st Apr 2020

A new QAA has been added to the RDTC/GMMMG websites “Can patients with active cancer currently prescribed low molecular weight heparin (LMWH) for the treatment of a deep vein thrombosis (DVT) or pulmonary embolism (PE) be switched to a direct-acting oral anticoagulant (DOAC)”. This enquiry and subsequent answer has been developed by RDTC with input from oncology colleagues across the region, and discusses which DOACs (although not specifically licensed in patients with active cancer) can be considered for patients with active cancer and a confirmed proximal DVT or PE.